← Back to Clinical Trials
Recruiting NCT07447635

NCT07447635 Testing an MBI for Smoking Cessation and Alcohol Use Among Cancer Survivors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07447635
Status Recruiting
Phase
Sponsor H. Lee Moffitt Cancer Center and Research Institute
Condition Smoking Cessation
Study Type INTERVENTIONAL
Enrollment 600 participants
Start Date 2026-05-15
Primary Completion 2029-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Mindfulness-Based Relapse Prevention for Smoking and Alcohol (MBRP-SA)Quitline Support

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 600 participants in total. It began in 2026-05-15 with a primary completion date of 2029-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will examine the efficacy of Mindfulness-Based Relapse Prevention for Smoking and Alcohol (MBRP-SA) compared to standard care among cancer survivors who smoke cigarettes and engage in at-risk alcohol use. Investigators will evaluate implementation outcomes through structured stakeholder interviews across medical centers, cancer-focused organizations, and community-based programs in Florida, and will conduct a cost-assessment and an incremental cost-effectiveness analysis of the two conditions.

Eligibility Criteria

Inclusion Criteria: * ≥18 years old * History of a cancer diagnosis at any point in lifetime * Smoked ≥1 cigarette/day in past month * At least one binge drinking episode in past month or exceeds weekly drinking limits * Motivated to quit smoking and modify alcohol use in next 30 days * Valid home address in Florida * English-speaking, reading, and writing ability Exclusion Criteria: * Pregnancy or lactation * Active psychotic disorder * History of severe alcohol withdrawal * Current use of tobacco cessation medication or other treatments to quit smoking * End-of-life or hospice care * Household member already enrolled

Contact & Investigator

Central Contact

Skye Dougan, MPH

✉ Skye.Dougan@moffitt.org

📞 813-745-4376

Principal Investigator

Christine Vinci, PhD

PRINCIPAL INVESTIGATOR

Moffitt Cancer Center

Frequently Asked Questions

Who can join the NCT07447635 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Smoking Cessation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07447635 currently recruiting?

Yes, NCT07447635 is actively recruiting participants. Contact the research team at Skye.Dougan@moffitt.org for enrollment information.

Where is the NCT07447635 trial being conducted?

This trial is being conducted at Tampa, United States.

Who is sponsoring the NCT07447635 clinical trial?

NCT07447635 is sponsored by H. Lee Moffitt Cancer Center and Research Institute. The principal investigator is Christine Vinci, PhD at Moffitt Cancer Center. The trial plans to enroll 600 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology